We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NasdaqGM - Nasdaq Real Time Price USD

Tevogen Bio Holdings Inc. (TVGN)

1.3700

+0.2800

(+25.69%)

At close: October 15 at 4:00 PM EDT

1.3700

0.00

(0.00%)

After hours: October 15 at 7:59 PM EDT

Key Events

Loading Chart for TVGN

9/21 12:03 PM

DELL

Previous Close 1.0900
Open 1.0000
Bid 1.3000 x 100
Ask 1.4200 x 100
Day's Range 0.8600 - 1.4500
52 Week Range 0.2560 - 21.0900
Volume 56,196,611
Avg. Volume 5,789,018
Market Cap (intraday) 233.786M
Beta (5Y Monthly) 0.31
PE Ratio (TTM) 22.83
EPS (TTM) 0.0600
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 4.20

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

--

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TVGN

87.69%

S&P 500

21.92%

1-Year Return

TVGN

87.37%

S&P 500

34.37%

3-Year Return

TVGN

85.95%

S&P 500

23.71%

5-Year Return

TVGN

85.95%

S&P 500

23.71%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Tevogen Bio Holdings Inc.

1.3700

+25.69%

Mkt Cap 233.786M

Industry Biotechnology

Bio-Path Holdings, Inc.

1.1500

+1.77%

Mkt Cap 2.935M

Industry Biotechnology

Rani Therapeutics Holdings, Inc.

2.1200

-33.33%

Mkt Cap 115.897M

Industry Biotechnology

Bright Minds Biosciences Inc.

38.49

+1,445.78%

Mkt Cap 171.813M

Industry Biotechnology

Longboard Pharmaceuticals, Inc.

59.08

+0.15%

Mkt Cap 2.298B

Industry Biotechnology

Tempest Therapeutics, Inc.

1.1700

+9.35%

Mkt Cap 29.493M

Industry Biotechnology

Conduit Pharmaceuticals Inc.

0.1027

-5.52%

Mkt Cap 9.86M

Industry Biotechnology

Scholar Rock Holding Corporation

28.54

+0.07%

Mkt Cap 2.577B

Industry Biotechnology

2.6000

-2.62%

Mkt Cap 136.14M

Industry Biotechnology

Gritstone bio, Inc.

0.0686

+27.04%

Mkt Cap 8.102M

Industry Biotechnology

Dogwood Therapeutics, Inc.

0.1550

+12.40%

Mkt Cap 206,501

Industry Biotechnology

Valuation Measures

    Annual 

As of 10/14/2024

Market Cap

186.01M
Enterprise Value

189.69M
Trailing P/E

18.88
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

2.93

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-593.01%
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-2.49M
Diluted EPS (ttm)

0.0600

Balance Sheet and Cash Flow

Total Cash (mrq)

1.14M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

10.55M

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Analyst Price Targets

4.20

4.20 Average

1.3700 Current

4.20 High

TVGN does not have Company Insights

NKGN NKGen Biotech, Inc.

0.2300

-6.54%

CERO CERo Therapeutics Holdings, Inc.

0.0970

-1.72%

JTAI Jet.AI Inc.

0.0929

-8.92%

BOF BranchOut Food Inc.

1.7800

-3.26%

NIVF NewGenIvf Group Limited

1.9600

+159.77%

BDRX Biodexa Pharmaceuticals Plc

5.01

-2.72%

TWG Top Wealth Group Holding Limited

4.4500

-3.26%

ATPC Agape ATP Corporation

1.6700

-4.02%

NUKK Nukkleus Inc.

0.3010

-3.74%

TNON Tenon Medical, Inc.

3.4200

+0.59%

TGL Treasure Global Inc.

0.8356

0.00%

AIRE reAlpha Tech Corp.

1.2100

+1.68%

WBUY Webuy Global Ltd

0.1246

-0.32%

HWH HWH International Inc.

0.8340

+1.02%

CTNT Cheetah Net Supply Chain Service Inc.

0.2149

-0.60%

SMX SMX (Security Matters) Public Limited Company

2.6700

+7.66%